Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on developing innovative therapies for neuropsychiatric diseases, particularly its lead product, Caplyta (lumateperone), which has shown efficacy in treating schizophrenia and bipolar depression. The company operates primarily in the United States, leveraging its strong clinical data and proprietary drug formulation to differentiate itself in the competitive landscape of psychiatric medications.
Intra-Cellular generates revenue primarily through the sale of Caplyta, which is priced at approximately $1,200 per month per patient. The company benefits from a strong gross margin of 91.6%, indicating effective cost management in production and distribution. Its competitive advantage lies in the unique mechanism of action of Caplyta, which targets multiple neurotransmitter systems, providing a differentiated treatment option in a market dominated by older therapies.
FDA approvals for new indications or formulations of Caplyta
Changes in treatment guidelines for schizophrenia and bipolar disorder
Market penetration rates and patient adoption of Caplyta
Competitive landscape shifts, particularly from generic entrants
Regulatory changes impacting drug approval processes
Potential for increased competition from generic drugs as patents expire
Entry of new competitors with similar or superior drug formulations
Pricing pressure from generic alternatives
Limited cash flow generation, with negative operating and free cash flow
Dependence on a single product for revenue
low - The demand for psychiatric medications is relatively inelastic, as they are essential for patients regardless of economic conditions.
Minimal impact, as the company has negligible debt and financing costs are low. However, higher rates could affect overall healthcare spending.
minimal - The company has a debt/equity ratio of 0.01, indicating very low reliance on external financing.
growth - Investors are likely attracted to the potential for rapid revenue growth driven by Caplyta's market expansion.
high - The stock has shown significant price movements, with a 1-year return of 87.5%, indicating high volatility.
